Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management

American Journal of Hematology

Volumn 91, Issue 6, 2016, Pages 631-642

  Patnaik, Mrinal M ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTOKINE; DECITABINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASXL1 GENE; BLOOD SMEAR; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DNA METHYLATION; DRUG SAFETY; EPIGENETICS; FLOW CYTOMETRY; FRAMESHIFT MUTATION; GENE; GENETIC REGULATION; GENETIC TRANSCRIPTION; GROUPS BY AGE; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEOSOME; NUMERICAL CHROMOSOME ABERRATION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REMISSION; RISK ASSESSMENT; RNA SPLICING; SCORING SYSTEM; SURVIVAL TIME; AGED; DISEASE MANAGEMENT; FEMALE; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; PROGNOSIS;

AGED; DISEASE MANAGEMENT; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; PROGNOSIS; RISK ASSESSMENT;

EID: 84966930513     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24396     Document Type: Article

References (101)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
2. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: Focus on clinical practice. Mayo Clinic Proc 2016;91:259-272.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
4. Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 2014;28:2206-2212.
5. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
6. Ades L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013;37:609-613.
7. Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88:201-206.
8. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013;121:3005-3015.
9. Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994;87:743-745.
10. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
11. Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 2013; 122:2807-2811; quiz 2920.
12. Subari S, Patnaik M, Alfakara D, et al. Patients with therapy-related CMML have shorter median overall survival than those with de novo CMML: Mayo Clinic Long-Term follow-up experience. Clin Lymphoma Myeloma Leuk 2015;15:546-549.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-458.
14. Patnaik MM, Parikh SA, Hanson CA, et al. Chronic myelomonocytic leukaemia: A concise clinical and pathophysiological review. Br J Haematol 2014;165:273-286.
15. Mathew RA, Bennett JM, Liu JJ, et al. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res 2012;36:72-80.
16. Patnaik MM, Wassie EA, Lasho TL, et al. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol 2015;90:411-416.
17. Pophali PA, Patnaik MM. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J 2016;22:40-50.
18. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
19. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006;30:965-970.
20. Patnaik MM, Lasho TL, Finke CM, et al. Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. Am J Hematol 2016;91:E12-E14.
21. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550-566.
22. Pardanani A, Lasho T, Barraco D, et al. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. Am J Hematol 2016;91:E10-E11.
23. Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 2015;125:3618-3626.
24. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116:e74-e80.
25. Swerdlow S, Camp E, Harris NL, Jaffe ES, Stefano PA, Stein H, Thiele J, Vardiman JW, editor. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
26. Swederlow S, Camp E, Harris NL, Jaffe ES, Stefano PA, Stein H, Thiele J, Vardiman JW, editor. WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissue. Lyon: International Agency for Research on Cancer (IARC); 2008.
27. Bain BJ. What is a promonocyte? Am J Hematol 2013;88:919.
28. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007;31:1503-1509.
29. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 2002;99:840-849.
30. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375-383.
31. Tang G, Zhang L, Fu B, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 2014;89:813-818.
32. Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: A Mayo Clinic-French Consortium Study. Am J Hematol 2014;89:1111-1115.
33. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-1202.
34. Ernst T, Chase A, Zoi K, et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 2010;95:1473-1480.
35. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151:365-375.
36. Grossmann V, Kohlmann A, Eder C, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011;25:877-879.
37. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345.
38. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008;8:299.
39. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.
40. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
41. Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27:6109-6116.
42. Daver N, Strati P, Jabbour E, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 2013;88:56-59.
43. Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML. Leukemia 2013;27:2100-2102.
44. Damm F, Itzykson R, Kosmider O, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013;27:1401-1403.
45. Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 2013;27:1441-1450.
46. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180-193.
47. Balasubramani A, Larjo A, Bassein JA, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun 2015;6:7307.
48. Yamazaki J, Taby R, Vasanthakumar A, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012;7:201-207.
49. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013;121:3563-3572.
50. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-147.
51. Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J 2016;6:e385.
52. Patnaik MM, Wassie EA, Padron E, et al. Chronic myelomonocytic leukemia in younger patients: Molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J 2015; 5:e280.
53. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014.
54. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012;120:3080-3088.
55. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-572.
56. Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization defined myelodysplastic syndromes without excess blasts. Blood 2012;119:5674-5677.
57. Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007;109:713-717.
58. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
59. Ricci C, Fermo E, Corti S, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010;16:2246-2256.
60. Kuo MC, Liang DC, Huang CF, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009;23:1426-1431.
61. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011;118:3932-3941.
62. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010;116:3923-3932.
63. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013;121:2186-2198.
64. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J 2016;6:e393.
65. Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 2015;5:e333.
66. Germing U, Strupp C, Aivado M, et al. New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002;100:731-732; author reply 732-733.
67. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
68. Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-1510.
69. Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res 1998;22:871-878.
70. Nosslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferative CMML-A retrospective analysis of 91 patients from a single institution. Leuk Res 2001;25:741-747.
71. Breccia M, Latagliata R, Mengarelli A, et al. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: A retrospective analysis of 83 patients from a single institution. Haematologica 2004;89:866-868.
72. Cambier N, Wattel E, Menot ML, et al. All-trans retinoic acid in adult chronic myelomonocytic leukemia: Results of a pilot study. Leukemia 1996;10:1164-1167.
73. Gerhartz HH, Marcus R, Delmer A, et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group. Leukemia 1994;8:16-23.
74. Venditti A, Tamburini A, Buccisano F, et al. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Ann Hematol 2000;79:138-142.
75. Beran M, Estey E, O'Brien SM, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 1998;31:521-531.
76. Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999;17:2819-2830.
77. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 2006;107:1525-1529.
78. Feldman EJ, Cortes J, DeAngelo DJ, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008;22:1707-1711.
79. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
80. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006;106:1794-1803.
81. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase 2 trial. Blood 2011;118:3824-3831.
82. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011;117:2690-2696.
83. Fianchi L, Criscuolo M, Breccia M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: Results of an Italian retrospective study. Leuk Lymphoma 2013;54:658-661.
84. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29:2521-2527.
85. Thorpe M, Montalvao A, Pierdomenico F, et al. Treatment of chronic myelomonocytic leukemia with 5-azacitidine: A case series and literature review. Leuk Res 2012;36:1071-1073.
86. Wijermans PW, Ruter B, Baer MR, et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008;32:587-591.
87. Wong E, Seymour JF, Kenealy M, et al. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma 2013;54:878-880.
88. Padron E, Dezern A, Andrade-Campos M, et al. A multi-institution phase 1 trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res 2016 pii: clincanres.2781.2015. [Epub ahead of print]
89. Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 2013;121:5068-5077.
90. Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: Relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011;17:908-915.
91. Elliott MA, Tefferi A, Hogan WJ, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006;37:1003-1008.
92. Krishnamurthy P, Lim ZY, Nagi W, et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: A single-centre experience. Bone Marrow Transplant 2010;45:1502-1507.
93. Kroger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002;118:67-73.
94. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009;114:1545-1552.
95. Ocheni S, Kroger N, Zabelina T, et al. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 2009;43:659-661.
96. Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2015. doi: 10.1111/bjh.13576. [Epub ahead of print].
97. Park S, Labopin M, Yakoub-Agha I, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: A report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol 2013;90:355-364.
98. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-585.
99. Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis. J Clin Oncol 2013;31:2662-2670.
100. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012;30:4533-4540.
101. Kongtim P, Popat U, Jimenez A, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2016;22:47-53.